加拿大消化健康基金会公共影响系列：加拿大的胃食管反流病：发病率、患病率以及直接和间接经济影响。
Canadian Digestive Health Foundation Public Impact Series: gastroesophageal reflux disease in Canada: incidence, prevalence, and direct and indirect economic impact.
作者信息
Fedorak Richard N, Veldhuyzen van Zanten Sander, Bridges Ron
机构信息
Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada.
出版信息
Can J Gastroenterol. 2010 Jul;24(7):431-4. doi: 10.1155/2010/296584.
Abstract
The Canadian Digestive Health Foundation initiated a scientific program to assess the incidence, prevalence, mortality and economic impact of digestive disorders across Canada. The current article presents the updated findings from the study concerning gastroesophageal reflux disease - a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications (Montreal definition).
摘要
加拿大消化健康基金会发起了一项科学计划，以评估加拿大消化系统疾病的发病率、患病率、死亡率及经济影响。本文介绍了该研究中关于胃食管反流病的最新发现——当胃内容物反流引起不适症状和/或并发症时即会出现这种病症（蒙特利尔定义）。
相似文献
1
Canadian Digestive Health Foundation Public Impact Series: gastroesophageal reflux disease in Canada: incidence, prevalence, and direct and indirect economic impact.加拿大消化健康基金会公共影响系列：加拿大的胃食管反流病：发病率、患病率以及直接和间接经济影响。
Can J Gastroenterol. 2010 Jul;24(7):431-4. doi: 10.1155/2010/296584.
2
Canadian Digestive Health Foundation Public Impact Series. Inflammatory bowel disease in Canada: Incidence, prevalence, and direct and indirect economic impact.加拿大消化健康基金会公共影响系列。加拿大的炎症性肠病：发病率、患病率以及直接和间接经济影响。
Can J Gastroenterol. 2010 Nov;24(11):651-5. doi: 10.1155/2010/407095.
3
Canadian Digestive Health Foundation Public Impact Series 3: irritable bowel syndrome in Canada. Incidence, prevalence, and direct and indirect economic impact.加拿大消化健康基金会公共影响系列3：加拿大的肠易激综合征。发病率、患病率以及直接和间接经济影响。
Can J Gastroenterol. 2012 May;26(5):252-6. doi: 10.1155/2012/861478.
4
Canadian Digestive Health Foundation Public Impact Series 4: celiac disease in Canada. Incidence, prevalence, and direct and indirect economic impact.加拿大消化健康基金会公共影响系列4：加拿大的乳糜泻。发病率、患病率以及直接和间接经济影响。
Can J Gastroenterol. 2012 Jun;26(6):350-2. doi: 10.1155/2012/384787.
5
Canadian Digestive Health Foundation Public Impact Series 5: Pancreatitis in Canada. Incidence, prevalence, and direct and indirect economic impact.加拿大消化健康基金会公共影响系列5：加拿大的胰腺炎。发病率、患病率以及直接和间接经济影响。
Can J Gastroenterol. 2012 Aug;26(8):544-5. doi: 10.1155/2012/795149.
6
Epidemiology of gastroesophageal reflux disease.胃食管反流病的流行病学
Gastroenterol Clin North Am. 2014 Mar;43(1):1-14. doi: 10.1016/j.gtc.2013.11.006. Epub 2013 Dec 27.
7
Gastroesophageal reflux disease burden in Iran.伊朗的胃食管反流病负担
Arch Iran Med. 2015 Feb;18(2):85-8.
8
Focus on gastroesophageal reflux (GER) and laryngopharyngeal reflux (LPR): new pragmatic insights in clinical practice.关注胃食管反流（GER）和喉咽反流（LPR）：临床实践中的新实用见解。
J Biol Regul Homeost Agents. 2018;32(1 Suppl. 2):41-47.
9
[Gastroesophageal Reflux Disease].[胃食管反流病]
Korean J Gastroenterol. 2019 Feb 25;73(2):70-76. doi: 10.4166/kjg.2019.73.2.70.
10
Epidemiology and societal costs of gastroesophageal reflux disease and Barrett's syndrome in Germany, Italy and Spain.德国、意大利和西班牙胃食管反流病和 Barrett 综合征的流行病学和社会成本。
Expert Rev Pharmacoecon Outcomes Res. 2011 Apr;11(2):225-32. doi: 10.1586/erp.11.5.
引用本文的文献
1
Primary healthcare provider-perceived barriers to implementing an evidence-based pathway for undifferentiated lower gastrointestinal tract symptoms: A qualitative inquiry.初级医疗服务提供者认为在实施针对未分化下消化道症状的循证路径时存在的障碍：一项定性研究。
PLoS One. 2024 Dec 31;19(12):e0313201. doi: 10.1371/journal.pone.0313201. eCollection 2024.
2
Comparative Efficacy of Dexlansoprazole, Pantoprazole, Esomeprazole, and Rabeprazole in Achieving Optimal 24-Hour Intragastric pH Control: A Randomized Crossover Study Using Ambulatory pH Monitoring.右兰索拉唑、泮托拉唑、埃索美拉唑和雷贝拉唑在实现最佳24小时胃内pH值控制方面的疗效比较：一项使用动态pH监测的随机交叉研究。
Cureus. 2024 Oct 14;16(10):e71418. doi: 10.7759/cureus.71418. eCollection 2024 Oct.
3
The prevalence of gastrointestinal symptoms and cobalamin deficiency in patients with chronic urticaria.慢性荨麻疹患者胃肠道症状及钴胺素缺乏的患病率
Allergy Asthma Clin Immunol. 2023 Feb 24;19(1):14. doi: 10.1186/s13223-023-00771-w.
4
Cost-Utility Analysis of CYP2C19 Genotype Detection for Selection of Acid-Suppressive Therapy with Lansoprazole or Vonoprazan for Patients with Reflux Esophagitis in China.中国反流性食管炎患者应用兰索拉唑或沃诺拉赞进行抑酸治疗时 CYP2C19 基因型检测的成本-效用分析。
Clin Drug Investig. 2022 Oct;42(10):839-851. doi: 10.1007/s40261-022-01188-w. Epub 2022 Aug 22.
5
[Not Available].[无可用内容]
CMAJ. 2020 Nov 23;192(47):E1597-E1607. doi: 10.1503/cmaj.190814-f.
6
Are Anxious and Depressive Symptoms Associated with Gastrointestinal Symptoms in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL)?焦虑和抑郁症状是否与西班牙裔社区健康研究/拉丁裔研究（HCHS/SOL）中的胃肠道症状有关？
J Racial Ethn Health Disparities. 2021 Jun;8(3):712-722. doi: 10.1007/s40615-020-00831-6. Epub 2020 Aug 1.
7
Guideline on screening for esophageal adenocarcinoma in patients with chronic gastroesophageal reflux disease.慢性胃食管反流病患者食管腺癌筛查指南
CMAJ. 2020 Jul 6;192(27):E768-E777. doi: 10.1503/cmaj.190814.
8
The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.1990 年至 2017 年全球 195 个国家和地区胃食管反流病的全球、区域和国家负担：2017 年全球疾病负担研究的系统分析。
Lancet Gastroenterol Hepatol. 2020 Jun;5(6):561-581. doi: 10.1016/S2468-1253(19)30408-X. Epub 2020 Mar 13.
9
Screening for esophageal adenocarcinoma and precancerous conditions (dysplasia and Barrett's esophagus) in patients with chronic gastroesophageal reflux disease with or without other risk factors: two systematic reviews and one overview of reviews to inform a guideline of the Canadian Task Force on Preventive Health Care (CTFPHC).慢性胃食管反流病患者（有或无其他危险因素）的食管腺癌和癌前病变（异型增生和巴雷特食管）筛查：两项系统评价和一项综述评价，为加拿大预防保健特别工作组（CTFPHC）指南提供信息。
Syst Rev. 2020 Jan 29;9(1):20. doi: 10.1186/s13643-020-1275-2.
10
Epidemiologic trends and geographic distribution of esophageal cancer in Canada: A national population-based study.加拿大食管癌的流行病学趋势和地理分布：一项基于全国人口的研究。
Cancer Med. 2020 Jan;9(1):401-417. doi: 10.1002/cam4.2700. Epub 2019 Nov 12.
本文引用的文献
1
Symptomatic gastroesophageal reflux disease after lung transplantation.肺移植术后症状性胃食管反流病
Gen Thorac Cardiovasc Surg. 2009 Dec;57(12):647-53. doi: 10.1007/s11748-009-0486-1.
2
Characteristics of gastroesophageal reflux and potential risk of gastric content aspiration in children with cystic fibrosis.囊性纤维化患儿胃食管反流的特征及胃内容物吸入的潜在风险。
J Pediatr Gastroenterol Nutr. 2010 Feb;50(2):161-6. doi: 10.1097/MPG.0b013e3181acae98.
3
Pediatric gastroesophageal reflux disease and acid-related conditions: trends in incidence of diagnosis and acid suppression therapy.小儿胃食管反流病和酸相关疾病：诊断和抑酸治疗发病率的趋势。
J Med Econ. 2009;12(4):348-55. doi: 10.3111/13696990903378680.
4
Healthcare costs of GERD and acid-related conditions in pediatric patients, with comparison between histamine-2 receptor antagonists and proton pump inhibitors.儿科患者胃食管反流病（GERD）及酸相关病症的医疗费用，组胺-2受体拮抗剂与质子泵抑制剂的比较
Curr Med Res Opin. 2009 Nov;25(11):2703-9. doi: 10.1185/03007990903307755.
5
Gastroesophageal reflux disease (GERD): risk factors, and impact on quality of life-a population-based study.胃食管反流病（GERD）：危险因素及其对生活质量的影响——一项基于人群的研究
J Clin Gastroenterol. 2009 Feb;43(2):111-7. doi: 10.1097/MCG.0b013e31815ea27b.
6
Systematic review: persistence and severity in gastro-oesophageal reflux disease.系统评价：胃食管反流病的持续性和严重程度
Aliment Pharmacol Ther. 2008 Oct 1;28(7):841-53. doi: 10.1111/j.1365-2036.2008.03804.x. Epub 2008 Jul 12.
7
Comparison of gastro-oesophageal reflux disease and heartburn diagnoses in UK primary care.英国初级医疗中胃食管反流病与烧心诊断的比较。
Curr Med Res Opin. 2006 Sep;22(9):1661-8. doi: 10.1185/030079906X120986.
8
Review article: the long-term use of proton-pump inhibitors.综述文章：质子泵抑制剂的长期使用
Aliment Pharmacol Ther. 2005 Aug;22 Suppl 1:55-63. doi: 10.1111/j.1365-2036.2005.02611.x.
9
The impact of illness in patients with moderate to severe gastro-esophageal reflux disease.中重度胃食管反流病患者疾病的影响
BMC Gastroenterol. 2005 Jul 10;5:23. doi: 10.1186/1471-230X-5-23.
10
Epidemiology of gastro-oesophageal reflux disease: a systematic review.胃食管反流病的流行病学：一项系统综述。
Gut. 2005 May;54(5):710-7. doi: 10.1136/gut.2004.051821.
Zotero 插件